A postmenopausal female presenting with sacral pain only on movement—what is the appropriate evaluation and management?

Sacral Insufficiency Fracture Until Proven Otherwise—Obtain MRI Immediately

A postmenopausal woman with sacral pain only on movement most likely has a sacral insufficiency fracture, and MRI without contrast is the definitive diagnostic test that should be obtained promptly to confirm the diagnosis and exclude other pathology.

Diagnostic Approach

Initial Imaging Strategy

Start with plain radiographs of the pelvis and lumbar spine 1, 2. However, understand that radiographs have low sensitivity (30-70%) for sacral insufficiency fractures due to overlying bowel gas, soft tissue, and sacral curvature 1. The characteristic findings may not appear for 10-14 days after symptom onset 2.

If radiographs are negative or indeterminate (which is common), proceed immediately to MRI 1, 2. Do not wait for follow-up radiographs in a postmenopausal woman with this presentation—the clinical suspicion is too high.

Why MRI is the Gold Standard

MRI without contrast demonstrates:

• Linear T1 hypointense and T2 hyperintense signal representing bone marrow edema 1
• Fracture lines appearing as linear T1 and T2 hypointense signal 1
• The edema pattern is much more pronounced and linear on T2 than T1, distinguishing it from neoplasm (where the lesion is more obvious on T1) 1

Critical distinction: In-phase and out-of-phase MRI sequences reliably differentiate benign insufficiency fractures from pathologic fractures. Normal marrow shows signal suppression on opposed-phase images; tumors do not 1.

Alternative if MRI is Contraindicated

Bone scintigraphy can be used but has significant limitations 1:

• High sensitivity but poor specificity—cannot distinguish fracture from arthritis, infection, or metastases
• The "Honda sign" (H-shaped uptake) has 94% positive predictive value but is only present in 63% of sacral insufficiency fractures 1
• May be falsely negative in early presentation or in patients on corticosteroids 1

CT without contrast is less sensitive than MRI but can be used when MRI results are equivocal 2.

Comprehensive Evaluation for Underlying Osteoporosis

Once the fracture is confirmed, this patient requires immediate evaluation for osteoporosis and secondary causes 3, 4:

Laboratory Work-Up

Obtain the following to exclude secondary osteoporosis 3:

• Complete blood count
• Comprehensive metabolic panel (calcium, phosphorus, alkaline phosphatase, creatinine)
• 25-hydroxyvitamin D
• Thyroid-stimulating hormone
• Parathyroid hormone if calcium is abnormal
• Consider: serum protein electrophoresis, tissue transglutaminase antibodies (celiac), 24-hour urine calcium

Bone Density Assessment

DXA scan of lumbar spine and hip should be performed 4, 5. This establishes:

• Baseline BMD for treatment decisions
• T-score for diagnosis confirmation
• Monitoring parameters for therapy response

Fracture Risk Stratification

Use FRAX or other validated fracture risk assessment tool 4. A postmenopausal woman with a fragility fracture is automatically at high or very-high fracture risk and requires pharmacologic treatment 4.

Management Strategy

Immediate Management

• Pain control: Acetaminophen, NSAIDs if not contraindicated, or short-term opioids if severe
• Protected weight-bearing: Use assistive devices as needed
• Calcium 1000-1200 mg daily and vitamin D 800-1000 IU daily as adjunct therapy 6

Pharmacologic Treatment for Osteoporosis

Initiate treatment immediately—do not wait for fracture healing 4. For a postmenopausal woman with a fragility fracture (very-high-risk category):

First-line options 6, 4:

1. Bisphosphonates (alendronate, risedronate, zoledronic acid)—most cost-effective, longest experience
2. Denosumab 60 mg subcutaneously every 6 months—alternative if bisphosphonates not tolerated
3. Anabolic agents (teriparatide, abaloparatide, romosozumab)—consider for severe/multiple vertebral fractures or very-high-risk features

Specific considerations:

• If she has multiple or severe vertebral fractures, strongly consider starting with anabolic therapy (teriparatide, abaloparatide for 2 years, or romosozumab for 1 year) followed by antiresorptive 6, 4
• If she has gastroesophageal reflux, prefer denosumab or intravenous zoledronic acid over oral bisphosphonates 6
• Never stop denosumab without transitioning to another antiresorptive—this causes rebound bone loss and fracture risk 6, 4

Monitoring

• Reassess BMD by DXA every 1-3 years while on treatment 6
• Bone turnover markers (CTX for antiresorptives, P1NP for anabolics) at 3-6 months can identify non-adherence or poor response 6
• Consider bisphosphonate holiday after 5 years of oral or 3 years of IV therapy only if she transitions to low-moderate risk (T-score >-2.5, no new fractures) 6, 4

Red Flags Requiring Specialist Referral

Refer to endocrinology or osteoporosis specialist if 3, 4:

• Unexpectedly low BMD for age
• Recurrent fractures despite treatment
• Suspected secondary osteoporosis (abnormal labs)
• Premenopausal status (this would be highly unusual and suggests underlying disease)
• Complicating conditions (renal insufficiency, hyperparathyroidism, malabsorption)

Common Pitfalls to Avoid

1. Do not rely on radiographs alone—they miss most early sacral insufficiency fractures 1, 2
2. Do not delay treatment waiting for "fracture healing"—start osteoporosis therapy immediately 4
3. Do not assume pain is musculoskeletal or "arthritis" without imaging in a postmenopausal woman 1, 2
4. Do not stop denosumab without transitioning to another antiresorptive 6, 4
5. Do not overlook secondary causes—32-85% of women have contributing factors 3